Cellectis publishes manuscript in Frontiers Bioengineering and…
NEW YORK, November 10, 2022 (GLOBE NEWSWIRE) — Cellectis (the “Company”) CLLSa clinical-stage biotechnology company using its breakthrough gene-editing platform to develop life-saving cell and